"Prestorage Leukoreduction of Transfused Red Cells Is Associated with Significant Ongoing 2–12 Month Survival Benefit in Cardiac Surgery Patients." by Lynn Boshkov

Article

Prestorage Leukoreduction of Transfused Red Cells Is Associated with Significant Ongoing 2–12 Month Survival Benefit in Cardiac Surgery Patients.

Blood (2006)

Lynn Boshkov, Oregon Health & Science University
Grace Chien, Anesthesiology, Portland Veteran’s Administration Medical Center, Portland, OR, USA
Donna VanWinkle, Anesthesiology, Portland Veteran’s Administration Medical Center, Portland, OR, USA
Antony P. Furnary, Cardiothoracic Surgery, Providence St Vincent’s Medical Center, Portland, OR, USA
Yingxing Wu, Medical Data Research Center, Providence St Vincent’s Medical Center, Portland, OR, USA
Gary Grunkemeier, Medical Data Research Center, Providence St Vincent’s Medical Center, Portland, OR, USA
Cynthia D. Morris, Oregon Health & Science University

Link

Disciplines

Publication Date

November 16, 2006

DOI

10.1182/BLOOD.V108.11.578.578

Citation Information

Lynn Boshkov, Grace Chien, Donna VanWinkle, Antony P. Furnary, et al.. "Prestorage Leukoreduction of Transfused Red Cells Is Associated with Significant Ongoing 2–12 Month Survival Benefit in Cardiac Surgery Patients." Blood Vol. 108 Iss. 11 (2006) p. 578 - 578
Available at: http://works.bepress.com/gary-grunkemeier/66/